3‐Year Outcomes of Temperature‐Controlled Radiofrequency Ablation of the Posterior Nasal Nerve in Patients With Chronic Rhinitis
International Forum of Allergy & Rhinology · 2025
DOI: 10.1002/alr.23577 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift International Forum of Allergy & Rhinology, 2025. Verfasst von J Pablo Stolovitzky und 8 weiteren Autor:innen. Beteiligte Einrichtung: The Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Rhinitis, Radiofrequency Ablation, Nose. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Aerin Medical.
Abstract (Originalsprache)
Background
Temperature‐controlled radiofrequency (TCRF) ablation of the posterior nasal nerve has been shown to improve chronic rhinitis (CR) symptoms and quality of life (QoL). This study assesses the durability of TCRF's effectiveness and safety 3 years post‐procedure in patients with perennial allergic CR and nonallergic CR. Methodology This prospective, multicenter, single‐blinded, randomized controlled trial included a sham control arm and long‐term follow‐up. Analysis combined patients from the active treatment and control crossover arms. Outcomes include reflective total nasal symptom score (rTNSS), postnasal drip (PND), and cough scores, as well as QoL measured by the Mini Rhinoconjunctivitis Quality‐of‐Life Questionnaire (MiniRQLQ).
Results
Of 104 patients who underwent TCRF, 59 participated in the 3‐year follow‐up. The baseline mean rTNSS was 8.2 (95% confidence interval [95% CI, 7.9–8.6]), reduced to 3.5 (95% CI, 2.9–4.1) at 3 years, a 57.3% reduction and mean change of −4.7 (95% CI, −5.3 to −4.1; p < 0.0001). Most patients (79.7%) were responders. Cough scores decreased from a mean baseline of 1.5 (95% CI, 1.3–1.7) to 0.7 (95% CI, 0.5–0.9; mean change, −0.8; p < 0.0001). PND symptoms were also reduced from 2.5 (95% CI, 2.4 – 2.7) to 1.4 (95% CI, 1.2–1.7; mean change, −1.1; p < 0.0001). No severe adverse events were reported throughout the study, and no adverse events were reported between 24 months and 36 months of follow‐up.
Conclusion
TCRF ablation of the posterior nasal nerve provided sustained safety and improvement in CR symptoms, cough, postnasal drip, and patient‐reported QoL at 3 years, supporting its long‐term safety and efficacy in CR.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- The Department of Otolaryngology, Emory University School of Medicine, Atlanta, Georgia, USA.
- Sacramento Ear Nose and Throat Medical and Surgical Group, Roseville, California, USA.
- Madison ENT & Facial Plastic Surgery, New York, New York, USA.
- Department of Otorhinolaryngology-Head and Neck Surgery, Rush University Medical Center, Chicago, Illinois, USA.
- Ear, Nose, and Throat Associates of Texas, McKinney, Texas, USA.
- Ear & Sinus Institute, Fort Worth, Texas, USA.
ORCID-Profile: J Pablo Stolovitzky, Ahmad R Sedaghat
Förderung
- Aerin Medical
Zitieren
APA
Stolovitzky, J. P., Ow, R. A., Silvers, S. L., Tajudeen, B. A., McDuffie, C. M., Dean, M., Sedaghat, A. R., Phillips, K., & Takashima, M. (2025). 3‐Year Outcomes of Temperature‐Controlled Radiofrequency Ablation of the Posterior Nasal Nerve in Patients With Chronic Rhinitis. International Forum of Allergy & Rhinology. https://doi.org/10.1002/alr.23577
Vancouver
Stolovitzky JP, Ow RA, Silvers SL, Tajudeen BA, McDuffie CM, Dean M, et al. 3‐Year Outcomes of Temperature‐Controlled Radiofrequency Ablation of the Posterior Nasal Nerve in Patients With Chronic Rhinitis. International Forum of Allergy & Rhinology. 2025. doi:10.1002/alr.23577
BibTeX
@article{Stolovitzky2025,
author = {Stolovitzky, J Pablo and Ow, Randall A and Silvers, Stacey L and Tajudeen, Bobby A and McDuffie, Chad M and Dean, Marc and Sedaghat, Ahmad R and Phillips, Katie and Takashima, Masayoshi},
title = {3‐Year Outcomes of Temperature‐Controlled Radiofrequency Ablation of the Posterior Nasal Nerve in Patients With Chronic Rhinitis},
journal = {International Forum of Allergy & Rhinology},
year = {2025},
doi = {10.1002/alr.23577}
}
EUVIMED